BRCA1 and cancer: Preclinical studies have revealed a significant synergism between PARPi and ICIs in a range of cancer settings, irrespective of BRCA1/2 deficiency [100,119,280], strengthening the hypothesis that combined treatment can represent a valuable anti-cancer approach irrespective of the DNA repair condition, with important clinical consequences [281].